The Precision Peptide Company

Building a next-gen wellness platform focused on high-quality peptide formulations designed to support advanced health optimization.
CSE:BPC

[The Precision Peptide Company @PrecisionPepCo]

Read the Results Here: https://t.co/XbCiKSHLsg

[The Precision Peptide Company @PrecisionPepCo]

From development to verified.

The Precision Peptide Company CEO Pratap Sandhu on the lab results milestone that moves the BPC-157 transdermal patch from testing to credentialed analytical data. This is the inflection point.

[The Precision Peptide Company @PrecisionPepCo]

Read full release here: https://t.co/8D20mLdblb

[The Precision Peptide Company @PrecisionPepCo]

The Precision Peptide Company Secures 100% U.S. Compounding for All Peptides Including BPC-157 Under New 503A Pharmacy Agreement.

Under the Compounding Agreement, the Compounding Partner will provide the Company with access to large-scale pharmaceutical compounding infrastructure with the capacity to fulfill up to approximately 25,000 prescriptions per day across all U.S. states.

All peptides supplied to the Company's customers under the Compounding Agreement will be 100% compounded in the United States, in accordance with the regulatory framework governing 503A sterile compounding pharmacies and all other applicable U.S. federal and state regulatory requirements.

[The Precision Peptide Company @PrecisionPepCo]

https://t.co/hQyX6oefgq

[The Precision Peptide Company @PrecisionPepCo]

Pick the one you used to believe.
The category is harder to understand than it should be, which is why we built this in the first place.

CSE: BPC · OTCQB: PNGAF

[The Precision Peptide Company @PrecisionPepCo]

The category is harder to understand than it should be, which is why we built this in the first place.

[Dave Asprey @daveasprey]

Two days of breakthroughs, demos, real conversations, and a room full of people who refuse to accept average. The Beyond Biohacking Conference continues to raise the bar.

[The Precision Peptide Company @PrecisionPepCo]

Market projections are estimates. PCAC outcomes are not predictable. Contains Forward-looking information.

[The Precision Peptide Company @PrecisionPepCo]

How a $140B category went underground.
In September 2023, the FDA moved twelve peptides into Category 2 restriction.
Compounding pharmacies couldn't prepare them. Patients didn't stop wanting them. Chinese imports doubled in a year.
Then April 15, 2026 happened.

[The Precision Peptide Company @PrecisionPepCo]

https://t.co/hQyX6oefgq
CSE: BPC · OTCQB: PNGAF

[The Precision Peptide Company @PrecisionPepCo]

The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey’s BEYOND Conference in Austin, Texas

The Precious Peptide Company announces its participation in BEYOND, the biohacking, longevity, and consciousness conference founded and led by Dave Asprey, taking place May 27–29, 2026 in Austin, Texas. The Company will be the only peptide company exhibiting on the show floor and will operate a dedicated booth showcasing its peptide product line, including the needle-free BPC-157 transdermal patch.

Read Here: https://t.co/H67ar7hrwg

[The Precision Peptide Company @PrecisionPepCo]

20,000 patches. Ordered.

The Precision Peptide Company has placed a production order for 20,000 units of its BPC-157 transdermal patch — the Company's lead product candidate — in preparation for an initial commercial release as early as June 2026.

Each patch is formulated to deliver 2 mg of BPC-157, consistent with the independently verified potency reported on May 19, 2026 (95.5% purity · 2.02 mg per patch, Miraxis Labs).

Full release at https://t.co/SJuSbprKye

CSE: BPC · OTCQB: PNGAF

[The Precision Peptide Company @PrecisionPepCo]

The Precision Peptide Company Places Order for 20,000 BPC-157 Transdermal Patches

Today we have announced that we have placed an order for 20,000 units of our BPC-157 transdermal patch, the Company’s lead product candidate. The order is intended to support the Patch’s planned commercial release.
Each Patch is formulated to deliver 2 mg of BPC-157. An initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website.

Read More: https://t.co/z1WAPKiE1j

[The Precision Peptide Company @PrecisionPepCo]

@MMA_NYSE Stay close to the launch.
https://t.co/6yDPWxJ4Mw

[The Precision Peptide Company @PrecisionPepCo]

The global combat sports community is going needle-free.
The Precision Peptide Company has secured exclusive marketing rights into @MMA_NYSE 's global combat sports ecosystem; 5M+ followers, 530K user profiles, 18K+ gyms, 16 countries.
https://t.co/WZebfZ8nMp's roster includes @John_Kavanagh , @TheNotoriousMMA , @DonaldJTrumpJr , and @laura_sanko.

CSE: BPC | OTCQB: PNGAF

[The Precision Peptide Company @PrecisionPepCo]

@MMA_NYSE Lets walk you through the deal, the ecosystem, and the science behind it.

[The Precision Peptide Company @PrecisionPepCo]

The Precision Peptide Company Expands on Exclusive 50/50 Revenue Share Peptide Partnership with https://t.co/WZebfZ8nMp

We are providing additional details on our previously announced Exclusive Strategic Marketing Agreement with Mixed Martial Arts Group Limited @MMA_NYSE
, and outline the strategic significance of the partnership for the our commercialization roadmap.

Read More: https://t.co/Lok9pRKKTJ

[The Precision Peptide Company @PrecisionPepCo]

https://t.co/6yDPWxJ4Mw
Please Note: Category 2 removal is not FDA approval. PCAC outcomes are not predictable. Not investment advice.

[The Precision Peptide Company @PrecisionPepCo]

On April 15, 2026, the FDA moved twelve peptides out of Category 2 restriction and into PCAC scientific review.
The Precision Peptide Company already manufactures patch-delivered peptides containing three of them.

CSE: BPC | OTCQB: PNGAF